上市企业调查（Investigation of listed companies）.docVIP

上市企业调查（Investigation of listed companies） First place (last year 1) Pfizer: promises are not delivered [transcripts] annual sales of $48 billion 600 million (1%), net income of $8 billion 300 million (down 57%). About $12 billion 700 million (down 2%). This report disappointed investors, Jeffr** Kindler took over 20 months, he made the transition for the company to do their best, not only can not see the results, but the stock dropped 15% of the par value, fell to 10 year low. What is worse, like Pfizer and Merck take Wall Street as control, Richard Clark after he took office, in the face of patent expired, Vioxx withdrawal and lawsuits and other issues, a beautiful turnaround, the stock has rebounded 28% (recently by the Vyorin incident said the poor). The lawyer was born Jeffr** Kindler may also need more time to familiarize themselves with the pharmaceutical business, alone in the performance of hero, may not be fair. Moreover, many failed projects the company is not his hand director, he dare to take over courage, the ultimate outcome remains to be seen. But if before the Lipitor patent expires, Pfizer has not come up with a decent product and performance, did not make beautiful acquisitions, Wall Street may be more ruthless. Second place (last year 2) GSK: looking forward to the coming year [results] annual sales of 22 billion 700 million pounds (about $45 billion 100 million, down 2%), net income of 5 billion 200 million pounds (about $10 billion 300 million, down 3%), of which Advair income of 3 billion 500 million pounds (10% growth) vaccine, income of 2 billion pounds (20% growth), Lamictal (Lamictal) income of 1 billion 100 million euros (18% growth), the both the income of 1 billion 200 million pounds (down 22%), Coreg income of 587 million pounds (down 18%); Wellbutrin income of 529 million pounds (down 37%). Competition from generic drugs and Avandia sales continued to decline, and GSKs performance is flat and will be affected this year. But if consider